Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma
Dan Zou, Sitong Feng, Bowen Hu, Mengya Guo, Yan Lv, Rong Ma, Yuxin Du, Jifeng Feng · 2024
Read Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma by Dan Zou, Sitong Feng, Bowen Hu, Mengya Guo, Yan Lv, Rong Ma, Yuxin Du, Jifeng Feng (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11585172.txt.
Description
B-cell lymphoma returns after treatment too often, and the proteins that read the cell's chemical tags are drawing drug hunters' eyes. Dan Zou and seven co-authors survey that hunt in a 2024 review. The proteins, called bromodomains, come in eight families and read acetyl marks on the packaging of DNA, switching genes on.
Most work so far targets one family, BET, with inhibitor drugs used alone or alongside other treatments. Newer degraders, which destroy the protein instead of just blocking it, beat inhibitors in lab models. Inhibitors aimed at the other seven families are now showing anti-tumor activity too. The authors map the mechanism of each family and the compounds in play, arguing the whole bromodomain shelf, not just its famous corner, deserves clinical attention.
Catalog record
| CREATOR | Dan Zou, Sitong Feng, Bowen Hu, Mengya Guo, Yan Lv, Rong Ma, Yuxin Du, Jifeng Feng |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |